Don’t expect immediate impact of US tariff threat, price cuts on business, says Cipla head

Cipla does not expect any immediate impact from potential tariffs imposed by the US on pharmaceutical imports or from US President Trump’s recent order to bring down prescription drug prices, the company’s managing director and global CEO, Umang Vohra, said.

“I think our business continues as usual, there’s not been any stoppage at any place in the US on account of any confusion with respect to tariffs…and so, we don’t see the impact,” Vohra said. He added that the company is monitoring ongoing developments, including trade talks between the US and Indian governments.